Raised
$129M
Investors
262
Min Invest
None stated
Is this your company or fund? Claim this page free.
AltStreet Analysis
·Generated from EDGAR primary sources
Oncology Impact Fund 2 (iCapital), L.P. is a Delaware pooled investment fund that has raised $129.3M from 262 investors under Rule 506(b) and Section 3(c) exemptions. This amended filing was submitted on May 3, 2021, by iCapital PE GP, LLC as promoter, with Justin Lioi listed as executive officer. No first sale date or minimum investment amount was disclosed on the filing.
This is a pooled investment fund utilizing the standard 506(b) private placement exemption combined with Investment Company Act Section 3(c) exclusion, typical for institutional alternative funds. The $494K average commitment per investor and 262-investor count suggest a platform-distributed fund targeting accredited investors at accessible minimums, consistent with iCapital's technology-enabled alternative investment platform model.
Data Flags
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing May 3, 2021
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
AltStreet Coverage
Original reporting from AltStreet's daily EDGAR monitoring covering iCapital and its filings.
Blue Owl Net Lease Trust Form D/A: Investors and Dollars Sold Both Rise 46% in a Year to $9.2 Billion
A Form D/A filed August 27 puts Blue Owl Real Estate Net Lease Trust at 44,524 investors and $9.2 billion sold since inception, both up about 46% from the amendment filed a year earlier, as its September closing added $178.6 million and the $2.45 billion Sila Realty Trust take-private closed on credit-facility borrowings.
Platform coverage · Sep 2026
What Is a Form D Amendment? KKR Infrastructure V's D/A Tops $17 Billion
A Form D amendment updates an existing exempt-offering notice rather than announcing a new raise, and a 2026 filing from a KKR infrastructure fund shows exactly how that distinction plays out in the numbers.
Platform coverage · Sep 2026
iCapital-PEG Evergreen PE Offshore Fund Reports $414M Raised, Up 113% in One Year
A Form D/A filed July 20, 2026 shows total offering proceeds for the iCapital-managed Cayman segregated portfolio company more than doubled versus the prior annual amendment, with investor headcount rising 37% to 224.
Platform coverage · Aug 2026
From 49 to 92 Investors in a Year: A 1972-Vintage Quant Shop Is Quietly Winning the Wealth Channel
The annual Form D amendment iCapital filed August 19 for its Campbell Absolute Return feeder is the kind of document nobody reads — except this one measured something: an 88% jump in investors and $12 million of new capital in twelve months, the largest single-year move AltStreet has recorded for the entity, and a direct reading on how wealth advisers are buying systematic absolute return.
Platform coverage · Aug 2026
iCapital's Blue Owl GP Stakes VI Feeders Report Nearly $816M Sold
The onshore and offshore private-wealth vehicles tied to Blue Owl's GP Stakes VI strategy reported a combined $815.8 million sold and 1,580 investor positions in Aug. 13 SEC amendments, up $16.45 million from their July 2025 filings. The filings show the scale of the iCapital distribution channel, but not when the incremental capital actually arrived.
Platform coverage · Aug 2026
Capital Raise Timeline
2 Form D filings from May 14, 2020 to May 3, 2021, the latest a D/A.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
dark
Fund family Part of the Oncology Impact Fund family: 2 vehicles across 1 generation · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- The dated record: 14 facts with source, effective date and capture date, viewable as AltStreet knew them on any past day
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 177513 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a other private fund
Auditor named on Form ADV: Kpmg LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
-- iCapital PE GP, LLC
Promoter · New York, NY
Justin Lioi
Executive Officer · New York, NY
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
UBS Financial Services Inc.CRD 8174 on BrokerCheck
Weehawken, NJ · Soliciting in all states
Questions About Oncology Impact Fund 2 (iCapital), L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Oncology Impact Fund 2 (iCapital), L.P.?
Oncology Impact Fund 2 (iCapital), L.P. is a Delaware limited partnership that filed a Form D with the SEC on May 3, 2021 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of equity and pooled investment fund interests. AltStreet links the issuer to iCapital.
Is Oncology Impact Fund 2 (iCapital), L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. Oncology Impact Fund 2 (iCapital), L.P. filed a Form D with the SEC on May 3, 2021 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $129,337,000 sold to 262 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to iCapital, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Oncology Impact Fund 2 (iCapital), L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Oncology Impact Fund 2 (iCapital), L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Oncology Impact Fund 2 (iCapital), L.P. raised?
Oncology Impact Fund 2 (iCapital), L.P. reported $129,337,000 sold from 262 investors in an offering of indefinite size as of the Form D filed May 3, 2021.
Who can invest in Oncology Impact Fund 2 (iCapital), L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Oncology Impact Fund 2 (iCapital), L.P.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Oncology Impact Fund 2 (iCapital), L.P. and how are they paid?
The Form D names UBS Financial Services Inc. (CRD 8174) as the recipient of sales compensation soliciting in all states.
Who is behind Oncology Impact Fund 2 (iCapital), L.P.?
The Form D lists 2 related persons: iCapital PE GP, LLC, promoter (General Partner); Justin Lioi, executive officer (Senior Vice President of the Sole Member of the General Partner). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Oncology Impact Fund 2 (iCapital), L.P. located?
The issuer's address on its SEC filings is C/O Icapital Pe Gp, LLC, 60 East 42nd Street, 26th Floor, New York, NY 10165. Its phone number of record is (212) 994-7400. It is organized under the laws of Delaware.
How long is the Oncology Impact Fund 2 (iCapital), L.P. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.
How large is Oncology Impact Fund 2 (iCapital), L.P.?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.